Ultragenyx Pharmaceuticals disappointed investors with Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta. Shares fell 43.5%, as two studies failed to meet primary endpoints. Analysts slashed price targets on Ultragenyx stock, prompting caution. The company plans to release Phase 3 data for Angelman syndrome treatment GTX-102.

In response to disappointing Phase 3 results for setrusumab, Ultragenyx Pharmaceuticals saw a significant drop in its stock price. Analysts at firms like Cantor Fitzgerald, Barclays, and Citigroup reduced their price targets on Ultragenyx stock. Investors may want to wait for further data before considering investment in the company.

Ultragenyx Pharmaceuticals faced setbacks as its Phase 3 studies for setrusumab did not meet primary endpoints, leading to a decline in stock price. CEO Dr. Emil Kakkis expressed surprise and disappointment. Osteogenesis imperfecta affects 20,000 to 50,000 people in the United States. Analysts have revised price targets on Ultragenyx stock.

Firms like Cantor Fitzgerald, Barclays, and Citigroup have cut their price targets on Ultragenyx stock following disappointing Phase 3 results for setrusumab. Investors are advised to exercise caution. The company plans to release data on GTX-102 for Angelman syndrome treatment.

Ultragenyx Pharmaceuticals faced a setback with disappointing Phase 3 results for setrusumab, causing a sharp decline in stock price. Analysts have revised their price targets on Ultragenyx stock, advising investors to wait for more data before considering investment. The company plans to provide data on GTX-102 for Angelman syndrome treatment.

Read more at Yahoo Finance: Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today